LVIS支架与Enterprise支架辅助弹簧圈栓塞治疗颅内动脉瘤的系统综述与Meta分析
该系统综述与Meta分析纳入5项观察性研究共912例患者(LVIS组457例,Enterprise组455例),比较两种支架辅助弹簧圈栓塞颅内动脉瘤的临床与血管造影结局。LVIS组Raymond-Roy闭塞分级3级(RR 0.30;95%CI 0.13-0.71;I²=0%)及动脉瘤再通(RR 0.38;95%CI 0.18-0.82;I²=0%)风险显著低于Enterprise组,其余结局无统计学显著差异。作者认为LVIS可能通过降低复发和不完全闭塞风险提供更好的血管造影结局,但需随机对照试验进一步证实。
要点
- LVIS组RROC 3级风险显著低于Enterprise组(RR 0.30;95%CI 0.13-0.71;I²=0%)。
- LVIS组动脉瘤再通风险显著低于Enterprise组(RR 0.38;95%CI 0.18-0.82;I²=0%)。
- mRS 0-2、RROC 1或2级及神经功能缺损、支架内狭窄、出血或血栓栓塞事件两组无统计学显著差异。
核心结论
- LVIS与Enterprise支架在颅内动脉瘤血管内治疗中均安全有效,LVIS可能通过降低复发和不完全闭塞风险提供更好的血管造影结局,这些发现支持其在复杂动脉瘤治疗中的潜在优势,但需随机对照试验进一步证实。
研究设计与样本
- 系统综述与Meta分析,纳入5项观察性研究,共912例患者(LVIS组457例,Enterprise组455例),检索PubMed、Scopus和Embase数据库中比较LVIS与Enterprise支架的研究。
诊断标准与关键数值
- LVIS组RROC 3级风险显著低于Enterprise组(RR 0.30;95%CI 0.13-0.71;I²=0%);LVIS组动脉瘤再通风险显著低于Enterprise组(RR 0.38;95%CI 0.18-0.82;I²=0%);两组mRS 0-2、RROC 1或2级及神经功能缺损、支架内狭窄、出血或血栓栓塞事件无统计学显著差异。
临床应用与阅片要点
- 作者认为LVIS可能通过降低复发和不完全闭塞风险提供更好的血管造影结局,支持其在复杂动脉瘤治疗中的潜在优势,但需随机对照试验进一步证实。
局限性
- 纳入研究均为观察性研究。
- 需随机对照试验进一步证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This systematic review and meta-analysis aimed to compare the clinical and angiographic outcomes of the LVIS versus the Enterprise stent for the treatment of intracranial aneurysms (IAs).
METHODS: Eligible studies were extracted from PubMed, Scopus, and Embase comparing LVIS/Enterprise. Data on angiographic occlusion rates, neurological deficits, in-stent stenosis, hemorrhagic complications, thromboembolic complications and aneurysm recanalization were analyzed with statistical methods.
RESULTS: 5 observational studies (912 patients: 457 treated with LVIS and 455 with Enterprise) were analyzed. LVIS was linked to a significantly lower likelihood of Raymond-Roy Occlusion Classification (RROC) Class 3 (RR 0.30; 95% CI 0.13-0.71; I²=0%) and aneurysm recanalization (RR 0.38; 95% CI 0.18-0.82; I²=0%). No statistically significant differences were found between the two groups regarding mRS 0-2, RROC Class 1 or 2, or the incidence of neurological deficits, in-stent stenosis, hemorrhagic or thromboembolic events.
CONCLUSION: LVIS and Enterprise demonstrate safety and efficacy in the endovascular management of IAs. LVIS may provide improved angiographic outcomes by lowering the risk of recurrence and incomplete occlusion. These findings support its potential advantage in treating complex aneurysms. Further confirmation through randomized controlled trials (RCT) is needed.
引用
- Tamara Alves Carretta L, Ribeiro Gonçalves O, Lee Han M, et al. LVIS versus enterprise stents for stent-assisted coiling of intracranial aneurysms: a systematic review and meta-analysis. Neuroradiology. 2025. PMID: 41034591. doi:10.1007/s00234-025-03748-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。